期刊
CLINICAL SCIENCE
卷 130, 期 24, 页码 2267-2276出版社
PORTLAND PRESS LTD
DOI: 10.1042/CS20160536
关键词
chemoresistance; dicumarol; pregnancy specific beta-1-glycoprotein 1 (PSG1)
资金
- China National Natural Science Foundation [81572940, 81622007, 91439131, 31550006]
- Natural Science Foundation for Distinguished Young Scholars of Jiangsu Province [BK20140004]
- National High Technology Research and Development Program (863 Program) of China [SQ2015AA020948]
- Fundamental Research Funds for the Central Universities [JUSRP51311A, JUSRP51615B]
Chemotherapeutic response is critical for the successful treatment and good prognosis in cancer patients. In this study, we analysed the gene expression profiles of preoperative samples from oestrogen receptor (ER)-negative breast cancer patients with different responses to taxane-anthracycline-based (TA-based) chemotherapy, and identified a group of genes that was predictive. Pregnancy specific beta-1-glycoprotein 1 (PSG1) played a central role within signalling pathways of these genes. Inhibiting PSG1 can effectively reduce chemoresistance via a transforming growth factor-beta (TGF-beta)-related pathway in ER-negative breast cancer cells. Drug screening then identified dicumarol (DCM) to target the PSG1 and inhibit chemoresistance to TA-based chemotherapy in vitro, in vivo, and in clinical samples. Taken together, this study highlights PSG1 as an important mediator of chemoresistance, whose effect could be diminished by DCM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据